Trial Profile
Phase I/IIa Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumor Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Advanced breast cancer; Anal cancer; Bladder cancer; Bone cancer; Colorectal cancer; Gastric cancer; Gynaecological cancer; Head and neck cancer; Liver cancer; Lung cancer; Oesophageal cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Salivary gland cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Cerulean Pharma; NewLink Genetics Corporation
- 16 Feb 2021 Results published in the Investigational New Drugs
- 21 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 23 Feb 2017 Status changed from recruiting to active, no longer recruiting.